Trials Focus on Improving Transplant Safety and Long-Term Success
Though progress has been substantial, islet transplantation remains an experimental procedure. Islet transplant studies here at the DRI will continue to focus on improving the safety and long-term success of cell replacement therapies.
Our Clinical Cell Transplant Program has several active protocols that will:
- Assess the safety and effectiveness of new drugs to prevent rejection.
- Assess the safety and effectiveness of other agents to improve islet engraftment and increase islet mass after transplantation.
- Assess the safety and effectiveness of co-transplanting selected immune cells to improve graft acceptance and promote long-term cell function.
- Identify markers that indicate early islet loss so we can develop intervention strategies to sustain islet function.
- Assess the safety and effectiveness of alternative transplant sites.
Current Clinical Trials:
We’re actively screening individuals for participation in the islet after kidney transplantation studies.
1. Islet After Kidney Transplant
2. Strategies to Improve Long Term Islet Graft Survival
For additional information on the trials and/or eligibility criteria, please call 305-243-5321 or send an email. You can also print out and complete the Islet Transplant Application form and fax it to 305-243-1058.
The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.